What Happened?
New York, NY-based Intercept-Pharmaceuticals Appointed Andrew Saik as Chief Financial Officer
About the Company
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
About the Person
Andrew Saik is Chief Financial Officer at Intercept Pharmaceuticals. Previously, Andrew held various senior HR leadership roles in the industry.
Info Source
News
Short Profile